Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-02-26 01:27:51 ET
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call February 25, 2026 4:30 PM EST...
Read the full article on Seeking Alpha
For further details see:
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Arcutis Biotherapeutics Inc.
NASDAQ: ARQT
ARQT Trading
1.9% G/L:
$24.94 Last:
110,343 Volume:
$25.12 Open:
ARQT Latest News
March 10, 2026 09:00:00 am
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology
March 05, 2026 09:00:00 am
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
March 03, 2026 08:00:00 am
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
February 27, 2026 04:00:00 pm
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference
ARQT Stock Data
$3,301,042,082
98,483,722
0.17%
104
N/A
Biotechnology & Life Sciences
Healthcare
US
Westlake Village
